Condition
MSA
Total Trials
5
Recruiting
1
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (1)
P 3 (1)
Trial Status
Completed1
Terminated1
Recruiting1
Not Yet Recruiting1
Active Not Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02315027Phase 1Active Not RecruitingPrimary
Mesenchymal Stem Cell Therapy in Multiple System Atrophy
NCT07465198Phase 2Not Yet Recruiting
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
NCT06647641Recruiting
The CurePSP Genetics Program
NCT03829657Phase 3Terminated
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT03033680Phase 1CompletedPrimary
Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA
Showing all 5 trials